NASH Or MASH Treatment Market Intelligence Report 2025-2033, Industry Developments, Market Drivers, Share & Industry Insights

NASH/MASH Treatment Market reached US$ 7.87 billion in 2024 and is expected to reach US$ 31.76 billion by 2033, growing at a CAGR of 17.7% during the forecast period 2025-2033. The approved drugs market value is reported at US$ 178.31 million in 2024 and is expected to reach US$ 16.82 billion in 2033 growing at a CAGR of 57.05%.

DataM Intelligence has published a new research report on "NASH/MASH Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

The stage 2-3 segment of the NASH/MASH treatment market was valued at US$ 3,237.06 million in 2024 and is projected to reach US$ 19,391.01 million by 2032, registering a robust CAGR of 27.2% during the forecast period (2025-2032).

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nash-or-mash-treatment-market?kb

Growth Dynamics

Treatment options for MASH include lifestyle interventions, bariatric surgery, and pharmacotherapy. Lifestyle changes focus on diet, weight loss, and regular exercise. Bariatric surgery is recommended for patients with a BMI ≥35 kg/m2, with or without diabetes. Pharmacotherapy is tailored to the underlying condition: GLP-1 receptor agonists for patients with type 2 diabetes, anti-obesity drugs such as statins for those with obesity, and vitamin E for non-diabetic patients. Recently, the U.S. FDA approved Resmetirom (Rezdiffra), the first-in-class therapy for adult MASH patients with moderate to advanced liver fibrosis.

In obese individuals, excessive fat buildup in the liver, known as Non-Alcoholic Fatty Liver Disease (NAFLD), can progress to more severe stages such as MASH. Around 20-30% of people with NAFLD develop MASH, driving the need for effective treatment options.

Type 2 diabetes is another key risk factor. Its global prevalence is rising rapidly, with the International Diabetes Federation projecting that by 2045, 1 in 8 adults-about 783 million people will have diabetes, marking a 46% increase. Over 90% of these cases will be type 2 diabetes.

Type 2 diabetes causes insulin resistance, a major metabolic dysfunction linked to fat accumulation in the liver a hallmark of MASH. In turn, fatty liver disease worsens insulin resistance, creating a self-perpetuating cycle.

The growing burden of obesity and diabetes has encouraged pharmaceutical companies to fast-track the development of novel MASH therapies. Many drugs are now in late-stage clinical trials, targeting pathways related to fibrosis, liver inflammation, and insulin resistance.

Key Players:

Novo Nordisk A/S, Boehringer Ingelheim International GmbH., 89bio, Inc., Inventiva., CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD, Sagimet Biosciences., and Akero Therapeutics, Inc

Key Development:

According to the Centers for Disease Control and Prevention (CDC), obesity affects 40.3% of U.S. adults, with similar rates among men and women. Over 38 million Americans-around 1 in 10-have diabetes, and 90-95% of these cases are type 2 diabetes. Additionally, nearly half of U.S. adults (about 116 million) have hypertension. The growing prevalence of these conditions is expected to drive a sharp increase in MASH cases. DataM estimates that the number of MASH cases in the U.S. was approximately 17.5 million in 2024 and is projected to reach 23.33 million by 2030.

In March 2024, the U.S. Food and Drug Administration (FDA) approved Rezdiffra (resmetirom), the first-in-class therapy for adults with MASH and moderate to advanced fibrosis (F2-F3). Developed by Madrigal Pharmaceuticals, Inc., Rezdiffra is a once-daily oral THR-β agonist that demonstrated strong safety and efficacy in the Phase 3 MAESTRO-NASH trial.

In October 2024, survodutide, a GLP-1 receptor agonist developed by Boehringer Ingelheim International GmbH, received the U.S. FDA Breakthrough Therapy Designation for treating adult MASH patients with moderate to advanced fibrosis (F2-F3).

Growth Forecast Projected:

The Global NASH/MASH Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global NASH/MASH Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=nash-or-mash-treatment-market?kb

Key Segments:

By Drug: (Resmetirom (Rezdiffra), Lanifibranor, Semaglutide, Survodutide, Pegozafermin, Efruxifermin, Denifanstat, Others)

By Stage: (Stage 0-1, Stage 2-3, Stage 4)

By Age-Group: (Pediatrics, Adults, Geriatrics)

By Gender :(Male, Female)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among NASH/MASH Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze NASH/MASH Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nash-or-mash-treatment-market?kb

FAQ's

Q1: How fast is the NASH/MASH Treatment Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 57.05% from 2025 to 2032

Q2: Which regions are dominating the NASH/MASH Treatment Market and which are fastest-growing?

A: North America dominating the NASH/MASH Treatment market.

Have any Query Ask here? @ https://www.datamintelligence.com/enquiry/nash-or-mash-treatment-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.